Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Financial Officer | August 31, 2026 | September 01, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 31, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,024 |
Ending reported balance
After 2026-08-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 57,187 · Balance 176,798 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. Row 2 · 2026-08-31 · Sale · Disposed 23,072 · Balance 153,726 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-31 · Sale · Disposed 11,514 · Balance 142,212 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-31 · Sale · Disposed 28,188 · Balance 114,024 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 3,813 |
Reported balance
After 2026-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-31 · Exercise / conversion · Disposed 57,187 · Balance 3,813 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENESEE & WYOMING INC
Report date December 30, 2019 · Filed December 30, 2019
Section 16 reporting ended · disclosed 2019-12-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-30 transaction · row 1
1 source rowRow 1 · 2019-12-30 · Disposition to issuer · Disposed 11,824 · Balance 0 F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration.
F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 1, 2026 20:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 57,187 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001649904-26-000023 · form4.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,813 Underlying: Common Stock · 57,187 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F5 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 28,188 | $106.20 | $2,993,647.35 |
DisclosureSEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,024 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 11,514 | $105.37 | $1,213,232.48 |
DisclosureSEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,212 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 23,072 | $104.59 | $2,413,033.57 |
DisclosureSEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,726 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 31, 2026 Filed Sep 1, 2026 20:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 57,187 | $25.79 | $1,474,852.73 |
DisclosureSEC source: 0001649904-26-000023 · form4.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $17.87 | $0.00 |
DisclosureSEC source: 0001104659-26-064516 · tm2615222-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 3,000 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are fully vested. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,000 | $17.87 | $53,610.00 |
DisclosureSEC source: 0001104659-26-064516 · tm2615222-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,099 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-26-022440 · tm267814-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,401 Underlying: Common Stock · 6,099 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are fully vested. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,099 | $6.80 | $41,473.20 |
DisclosureSEC source: 0001104659-26-022440 · tm267814-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 585 | $103.28 | $60,420.44 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 9 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,512 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F9 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 800 | $102.10 | $81,676.08 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 8 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,097 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F8 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,692 | $100.92 | $170,754.78 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 7 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,897 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F7 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,308 | $100.27 | $131,152.90 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,589 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 200 | $103.84 | $20,768.00 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,897 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,069 | $103.00 | $110,109.57 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,097 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 900 | $101.70 | $91,530.00 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,166 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 200 | $100.52 | $20,104.00 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,066 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,200 | $99.42 | $119,298.00 |
DisclosureSEC source: 0001104659-26-017729 · tm266887-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,266 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 100 | $100.10 | $10,010.00 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 10 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,466 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 800 | $98.99 | $79,192.48 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 9 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,566 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F9 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.54 to $99.40 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 400 | $97.67 | $39,068.52 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 8 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,366 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F8 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.18 to $97.85 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 292 | $96.26 | $28,108.71 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 7 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,766 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F7 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.04 to $96.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $98.47 | $0.00 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · derivative · entry 12 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2036-02-10 F12 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · derivative · entry 11 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F11 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F11 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 100 | $100.85 | $10,085.27 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,058 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.49 to $100.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 400 | $99.44 | $39,774.72 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,158 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.89 to $99.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,266 | $98.37 | $222,906.42 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,558 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.80 to $98.79 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 100 | $104.76 | $10,476.00 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,824 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 700 | $103.68 | $72,573.69 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,924 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.23 to $103.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2026 Filed Feb 13, 2026 01:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,913 | $102.66 | $196,379.78 |
DisclosureSEC source: 0001104659-26-014546 · tm266263-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,624 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $$102.09 to $103.02 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 23:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,381 | $106.06 | $358,599.00 |
DisclosureSEC source: 0001104659-26-011651 · tm265467-1_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,537 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 747 | $107.67 | $80,426.05 |
DisclosureSEC source: 0001104659-26-011651 · tm265467-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,918 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $107.32 to $108.08 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,000 | $106.60 | $106,604.00 |
DisclosureSEC source: 0001104659-26-011651 · tm265467-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,665 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.31 to $107.15 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,500 | $104.74 | $157,115.10 |
DisclosureSEC source: 0001104659-26-011651 · tm265467-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,665 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.34 to $104.99 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 10,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · derivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,237 Underlying: Common Stock · 10,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 6,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · derivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,925 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 10,750 | $108.99 | $1,171,642.50 |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,165 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 26,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009770 · tm264963-8_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,477 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · derivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,477 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,477 | $96.00 | $333,792.00 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,915 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,477 | $6.88 | $23,921.76 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 24,611 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,477 Underlying: Common Stock · 24,611 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 24,611 | $96.33 | $2,370,831.77 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,915 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.00 to $96.63 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 22:48 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 24,611 | $6.88 | $169,323.68 |
DisclosureSEC source: 0001104659-25-078815 · tm2523328-3_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 42,120 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-25-067431 · tm2520691-4_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,088 Underlying: Common Stock · 42,120 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 23,400 | $84.50 | $1,977,300.00 |
DisclosureSEC source: 0001104659-25-067431 · tm2520691-4_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,915 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,607 | $76.17 | $122,406.31 |
DisclosureSEC source: 0001104659-25-067431 · tm2520691-4_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,315 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $76.17 to $76.18 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 17,113 | $75.38 | $1,290,049.81 |
DisclosureSEC source: 0001104659-25-067431 · tm2520691-4_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,922 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $75.01 to $75.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.